7展望

　　目前临床上常用的PDT和TTT等疗法，主要针对的是CNV晚期的并发病变. 而基于对CNV生成机制的研究，寻找针对CNV病因、抑制新生血管生成的有效疗法，将为未来从根本上治愈CNV相关疾病提供可能.

　　新生血管生长是一个较为长期的过程，采用新生血管抑制因子治疗CNV需要寻找更为有效的方式. 随着材料科学的发展，基于大分子多聚体材料的眼内缓释、靶向给药系统表现出极大的应用潜力. 通过眼内注射或手术植入眼内，在病灶局部实现直接释药，拓展了眼内用药范围［29］. 另外，基因疗法也为新生血管抑制因子治疗CNV提供了手段. 采用基因转染方法，调控血管生成因子和抑制因子在局部组织的表达水平，可避免反复眼内注射给药的风险. 尽管目前在CNV治疗中还存在着许多问题，但相信，随着科学技术的进步，通过有效抑制CNV，从而防治这一类与CNV相关的严重致盲性眼病将成为可能.

　　【参考文献】

　　［1］ Folkman J, DAmore PA. Blood vessel formation: what is its molecular basis［J］?  Cell, 1996,87(7):1153-1155.

　　［2］ Hayreh SS. Ocular neovascularization ［J］. Arch Ophthalmo,1980,98(3):574.

　　［3］ Ambati J, Ambati BK, Yoo SH, et al. Agerelated macular degeneration: etiology, pathogenesis, and therapeutic strategies ［J］. Surv Ophthalmol, 2003,48(3):257-293.

　　［4］ Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization. Fiveyear results from randomized clinical trials ［J］. Arch Ophthalmol, 1994,112(4):500-509.

　　［5］ Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to agerelated macular degeneration. The influence of initial lesion size and initial visual acuity ［J］. Arch Ophthalmol, 1994,112(4):480-488.

　　［6］ Brancato R, Introini U, Bolognesi G, et al. ICGAguided laser photocoagulation of occult choroidal neovascularization in agerelated macular degeneration. Indocyanine green angiography ［J］. Retina, 2000,20(2):134-142.

　　［7］ Donati G, Kapetanios AD, Pournaras CJ. ICGguided laser photocoagulation of juxtafoveal and extrafoveal occult choroidal neovascularization ［J］. Graefes Arch Clin Exp Ophthalmol, 1999,237(11):881-886.

　　［8］ Desatnik H, Treister G, Alhalel A, et al. ICGAguided laser photocoagulation of feeder vessels of choroidal neovascular membranes in agerelated macular degeneration. Indocyanine green angiography ［J］. Retina, 2000,20(2):143-150.

　　［9］ Oosterhuis JA, Journeede Korver HG, KakebeekeKemme HM, et al. Transpupillary thermotherapy in choroidal melanomas ［J］. Arch Ophthalmol, 1995,113(3):315-321.

　　［10］ Reichel E, Berrocal AM, Ip M, et al. Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with agerelated macular degeneration ［J］. Ophthalmology, 1999,106(10):1908-1914.

　　［11］ SchmidtErfurth U, Miller J, Sickenberg M, et al. Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples ［J］. Graefes Arch Clin Exp Ophthalmol, 1998,236(5):365-374.

　　［12］ Barbazetto I, Burdan A, Bressler NM, et al. Treatment of AgeRelated Macular Degeneration with Photodynamic Therapy Study Group, Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatmentTAP and VIP report No.2 ［J］. Arch Ophthalmol, 2003,121(9):1253-1268.

　　［13］ 张美霞，陆方，严密，等. 光动力疗法治疗渗出型老年性黄斑变性四年临床观察总结［J］.中华眼底病杂志, 2004,20(5):275-279.

　　［14］ 张力，赵明威，黎晓新. 影响光动力疗法治疗脉络膜新生血管视力预后的多因素分析［J］.中华眼底病杂志, 2004,20(5):292-294.

　　［15］ Peyman GA, Blinder KJ, Paris CL, et al. A technique for retinal pigment epithelium transplantation for agerelated macular degeneration secondary to extensive subfoveal scarring ［J］. Ophthalmic Surg, 1991,22(2):102-108.

　　［16］ Hooper CY, Guymer RH. New treatments in agerelated macular degeneration ［J］. Clin Experiment Ophthalmol, 2003,31(5):376-391.

　　［17］ Miyamoto H, Kimura H, Yasukawa T, et al. Effect of focal Xray irradiation on experimental choroidal neovascularization ［J］. Invest Ophthalmol Vis Sci, 1999,40(7):1496-1502.

　　［18］ Chakravarthy U, MacKenzie G. External beam radiotherapy in exudative agerelated macular degeneration: a pooled analysis of phase I data ［J］. Br J Radiol, 2000,73(867):305-313.

　　［19］ Jaakkola A, Heikkonen J, Tommila P, et al. Strontium plaque brachytherapy for exudative agerelated macular degeneration: threeyear results of a randomized study ［J］. Ophthalmology, 2005,112(4):567-573.

　　［20］ 朱洁，王雨生，惠延年. 脉络膜新生血管的生成和抑制［J］. 眼科新进展, 2004,24(1):57-60.

　　［21］ 张鹏，惠延年，王雨生，等. PKC信号转导通路对缺氧人视网膜色素上皮细胞表达VEGF的作用［J］. 第四军医大学学报, 2003,24(21):1933-1934.

　　［22］ 赵炜，王雨生，张瑞，等. p42/p44 MAPK信号转导通路在缺氧诱导的人视网膜色素上皮细胞VEGF表达中的作用［J］. 眼科新进展, 2005,25(2):109-112.

　　［23］ 杨秀梅，王雨生，惠延年. 内源性脉络膜新生血管抑制因子的研究进展［J］. 国际眼科杂志, 2004,4(2):307-311.

　　［24］ 杨秀梅，王雨生，惠延年. 外源性脉络膜新生血管抑制剂的研究进展. 眼科新进展, 2005,25(1):75-78.

　　［25］ Siddiqui MA, Keating GM. Pegaptanib: in exudative agerelated macular degeneration ［J］. Drugs. 2005,65(11):1571-1577.

　　［26］ Gonzales CR, VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular agerelated macular degeneration with pegaptanib sodium: an exploratory analysis ［J］. Retina, 2005,25(7):815-827.

　　［27］ Michels S, Rosenfeld PJ. Treatment of neovascular agerelated macular degeneration with Ranibizumab/Lucentis ［J］. Klin Monatsbl Augenheilkd, 2005,222(6):480-484.

　　［28］ Slakter JS, Bochow TW, DAmico DJ, et al, Anecortave Acetate Clinical Study Group. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in agerelated macular degeneration. Ophthalmology, 2006,113(1):3-13.

　　［29］ 李越，王雨生，惠延年. 眼内缓释给药的研究现状［J］. 眼科新进展, 2005,25(5):464-466.

上一页  [1] [2]